A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Bolin ChenWenxiu YaoXingya LiGen LinQian ChuHailong LiuYingying DuJie LinHuaxin DuanHuijuan WangZemin XiaoHong SunLiyu LiuLi XuYan XuFang XuYi KongXingxiang PuKang LiQianzhi WangJia LiBaiyong LiYu XiaLin WuPublished in: British journal of cancer (2023)
NCT04646330.